Literature DB >> 17336080

Primary triple valve surgery for advanced rheumatic heart disease in Mainland China: a single-center experience with 871 clinical cases.

Qing-Qi Han1, Zhi-Yun Xu, Bao-Ren Zhang, Liang-Jian Zou, Jia-Hua Hao, Sheng-Dong Huang.   

Abstract

BACKGROUND: Triple valve surgery (TVS) is still of choice for advanced rheumatic heart disease (RHD), which has been associated with reported poor early and late outcomes. We describe the short- and long-term results after TVS in last two decades in Mainland China.
METHODS: From January 1985 to January 2005, a total of 871 patients (217 men, 654 women), with mean age of 42+/-11 years, underwent primary TVS for isolated advanced RHD. All patients received replacement procedures in mitral and aortic position (845 mechanical, 26 bioprosthetic), and 840 patients received repair procedures and the other 31 received replacement procedures in tricuspid position (9 mechanical, 22 bioprosthetic). Preoperative, perioperative, and postoperative data were retrospectively analyzed and risk factors affecting early and late survival were evaluated.
RESULTS: The 30-day hospital mortality was 8% (n=71). Presence of ascites, New York Heart Association (NYHA) class IV and lower left ventricular ejection fraction (LVEF) were identified as independent risk factors for hospital mortality. Overall long-term survival rate was 71%+/-3% at 5 years, and 59%+/-5% at 10 years. The cardiac survival rate was 75%+/-3% at 5 years and 63%+/-4% at 10 years. The event-free survival rate at 5 years and 10 years was 61%+/-6% and 41%+/-13%, respectively. Multivariate analysis revealed advanced age, NYHA class IV and lower LVEF were associated with increased late mortality. The freedom from thromboembolism and anticoagulation-related hemorrhage at 10 years was 90%+/-4% and 81%+/-5%, respectively. Of the 508 patients still alive, 376 (74%) were in NYHA class I and II.
CONCLUSIONS: Primary TVS for advanced RHD appears to offer satisfactory short- and long-term results with excellent symptomatic improvement. Cardiac-related late mortality following TVS may be improved by early surgical treatment before NYHA class IV or deterioration of LVEF occurs.

Entities:  

Mesh:

Year:  2007        PMID: 17336080     DOI: 10.1016/j.ejcts.2007.02.005

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  Short- and mid-term results of triple-valve surgery with an evaluation of postoperative quality of life.

Authors:  Saeed Davoodi; Abbasali Karimi; Seyed Hossein Ahmadi; Mehrab Marzban; Namvar Movahhedi; Kyomars Abbasi; Abbas Salehi Omran; Mahmood Shirzad; Mehrdad Sheikhvatan
Journal:  Tex Heart Inst J       Date:  2009

2.  Quadruple valve replacement for rheumatic valvular disease. Excellent durability for 20 years.

Authors:  A B Budak; K Korkmaz; H S Gedik; S B Genç; A Ü Yener; İ Alur; K Çağlı
Journal:  Herz       Date:  2014-04-11       Impact factor: 1.443

Review 3.  Pathophysiology and management of multivalvular disease.

Authors:  Philippe Unger; Marie-Annick Clavel; Brian R Lindman; Patrick Mathieu; Philippe Pibarot
Journal:  Nat Rev Cardiol       Date:  2016-04-28       Impact factor: 32.419

4.  Outcomes of tricuspid annuloplasty with and without prosthetic rings: a retrospective follow-up study.

Authors:  Wen-Jun Ren; Ben-Gui Zhang; Jia-Sheng Liu; Yong-Jun Qian; Ying-Qiang Guo
Journal:  J Cardiothorac Surg       Date:  2015-06-06       Impact factor: 1.637

5.  [Surgical treatment of tricuspid regurgitation associated with left valvular heart disease: about 162 cases].

Authors:  Amine Majdoub; Salaheddine Boulmakoul; Anas Elhafidi; Mohammed Messouak
Journal:  Pan Afr Med J       Date:  2021-12-23

6.  Medium long-term follow-up outcomes of BalMedic® bovine pericardial bioprosthetic valve in the mitral position.

Authors:  Sumin Yang; Haoyu Hu; Minghao Lin; Naiyan Gan
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

7.  Seventeen-millimeter St. Jude Medical Regent valve in patients with small aortic annulus: dose moderate prosthesis-patient mismatch matter?

Authors:  Jia Hu; Hong Qian; Ya-jiao Li; Jun Gu; Jing Janice Zhao; Er-yong Zhang
Journal:  J Cardiothorac Surg       Date:  2014-01-17       Impact factor: 1.637

8.  A single-center 14-year follow-up study of the BalMedic® bovine pericardial bioprosthetic valve.

Authors:  Minghao Lin; Naiyan Gan; Jun Chen; Kai Lv; Shengfu Han; Huazhen Huang
Journal:  Ann Transl Med       Date:  2020-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.